0.888
Rapt Therapeutics Inc stock is traded at $0.888, with a volume of 537.21K.
It is down -7.82% in the last 24 hours and up +13.55% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$0.9633
Open:
$0.9349
24h Volume:
537.21K
Relative Volume:
0.69
Market Cap:
$117.47M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-0.2911
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+18.37%
1M Performance:
+13.55%
6M Performance:
-15.43%
1Y Performance:
-80.65%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RAPT
Rapt Therapeutics Inc
|
0.888 | 99.24M | 3.25M | -116.80M | -98.17M | -3.05 |
![]()
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Nov-13-24 | Downgrade | Stifel | Buy → Hold |
Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
Feb-22-24 | Downgrade | UBS | Buy → Neutral |
Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-16-24 | Initiated | Evercore ISI | Outperform |
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Sep-14-23 | Initiated | Berenberg | Buy |
Aug-09-23 | Initiated | Stifel | Buy |
Jun-15-23 | Initiated | Barclays | Overweight |
Jan-04-23 | Initiated | Guggenheim | Buy |
Dec-01-22 | Initiated | Goldman | Buy |
Sep-21-22 | Initiated | CapitalOne | Overweight |
May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
Dec-09-21 | Initiated | JP Morgan | Overweight |
Aug-12-21 | Initiated | SVB Leerink | Outperform |
Jun-21-21 | Initiated | Piper Sandler | Overweight |
Jun-01-20 | Initiated | H.C. Wainwright | Buy |
May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
Apr-13-20 | Initiated | ROTH Capital | Buy |
Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
Nov-25-19 | Initiated | UBS | Buy |
Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks
RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN
RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com
Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com
Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance
RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada
RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks
RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus
RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire
Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-K Report - TradingView
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks
Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan
RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Leerink Partnrs Has Positive Outlook of RAPT FY2024 Earnings - Armenian Reporter
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):